AzTrials
AzTrials

AgingNCT02401893

Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults

An observational study of Aging, run by Vanderbilt University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI) antibodies after influenza vaccination in older adults so the investigators enrolled adults ≥50 years. Read more about this study

Who is it for?
Ages 50 years and olderHealthy volunteers can take part
Conditions the study is for
Aging
What is being tested?
Influenza Vaccine
Type of treatment
Vaccines
How many people
510 participants
Where
No sites listed yet
Study dates
Sep 2009to Jan 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Subjects were enrolled at Vanderbilt University Medical Center and Marshfield Clinic Research Foundation during September and October 2009. Subjects were eligible for recruitment if they were ≥50 years of age and had no previous allergy or reaction to influenza vaccination.

Who may be able to join

  • Age >=50 years

Who cannot join

  • Prior vaccine allergy or history of guillain barre

About this study

Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI) antibodies after influenza vaccination in older adults so the investigators enrolled adults ≥50 years.

Read the detailed description

In the United States, yearly influenza vaccination begins in August or September. However, influenza season can extend into April of the following year. The duration of protection from annual vaccination in older adults is unknown, and little is known about factors associated with the maintenance of response throughout the influenza season. This study evaluated factors associated with the immune response of older adults to trivalent influenza vaccine and the maintenance of antibody responses for the duration of the influenza season.

Subjects

Subjects were enrolled at two sites, Vanderbilt University Medical Center (Nashville, TN) and Marshfield Clinic Research Foundation (Marshfield, WI), during September and October 2009. Subjects were eligible for recruitment if they were ≥50 years of age and had no contraindication to influenza vaccination. Subject recruitment included advertisements at Vanderbilt University Medical Center and letters of invitation to older adults who had received an influenza vaccine in the year prior at Marshfield Clinic.1 All subjects were vaccinated either by their usual caregiver or by the study staff. Strain components for the 2009-2010 Northern Hemisphere vaccine included A/Brisbane/59/2007-like (H1N1), A/Brisbane/10/2007-like (H3N2), and B/Brisbane/60/2008-like. Participants were given the trivalent seasonal vaccine because the 2009 H1N1 pandemic vaccine was not available.

Data Collection

All subjects donated serum pre-vaccination (S1) during September through October 2009, 21 - 28 days post-vaccination (S2) and post-influenza season, May through July, 2010, approximately 250 days (8 months) post-vaccination (S3). Study procedures, informed consent documents and data collection forms were reviewed and approved by Institutional Review Boards at each of the study sites.

Age, co-morbid conditions, sex, and race were ascertained from participant interview. Recent chemotherapy, radiation therapy, or use of immunomodulating medications were ascertained by self-report or chart review. CDC-defined high risk medical conditions were identified by self-report of organ transplantation, cancer, diabetes mellitus, splenectomy (functional or anatomic), cardiovascular disease, renal disease, sickle cell disease, chronic pulmonary disease, seizure disorder, immune deficiency, or dementia.2 Self-reported stress was determined by asking participants to respond yes or no to the question "Have you suffered psychological stress or acute disease in the past 3 months?" included as part of the Mini Nutritional Assessment Questionnaire.3 Height and weight were measured by research study staff and body mass index (BMI) was calculated as weight (kg) / height (m)2.

Laboratory Methods

Blood samples were processed, stored, and shipped by each institution's local Sample Processing Core to Battelle (Columbus, OH). Hemagglutinin inhibition (HAI) testing was performed in duplicate against the influenza vaccine strains in the 2009-2010 Northern Hemisphere influenza vaccine. Although there is debate about the best correlate of protection for influenza,4 seroprotection was defined as an HAI titer of ≥40 since it is the correlate recognized by the United States Food and Drug Administration.5 Seroconversion was measured at S2 and defined as a four-fold rise in HAI post-influenza vaccination compared to pre-vaccination or ≥40 if S1 was <10. Maintenance of antibody response was measured in participants with an S2 ≥40, and defined as an S3≥40. If duplicate HAI results were discrepant by more than two fold, a third test was performed and the minimum result was recorded.

Statistical Analysis

Multivariable logistic regression models were run for the binary outcomes seroprotection at S2 and S3 and seroconversion at S2. Age, BMI, stress, high risk medical conditions (yes/no), female gender, study site and transformed S1 titer were included in all models. Time in days from S1 to S3 was included in models with S3 related outcomes as a continuous variable. Restricted cubic splines were applied to age and BMI. All raw HAI titers were log transformed using the method outlined by Beyer,6 changing dilution titers to integers with HAI <10 coded as 0, 10 as 1, 20 as 2, 40 as 3 and so on. Interaction terms between age and high risk status, and stress or age and sex were tested and were not included based on non-significant p values of overall interaction terms. Figures were generated by predicting the probability of having a HAI titer ≥40 by logistic regression. All analyses were done using R version 2.12.2.

Conditions
Aging
Being tested
Influenza Vaccine
Keywords
aging, influenza vaccine, immune responses
Medical subject headings
Influenza, Human

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Influenza VaccineBiological

    Everyone immunized as recommended by current guidelines

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maintenance of Immune Response using Hemagglutinin inhibition titers

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Mar 2015 (estimated)
  2. Study startSep 2009
  3. Primary completionJul 2010
  4. Study completionJan 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
510 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02401893
Sponsor's protocol ID
Serum 2009
Status last verified
May 2026
First submitted
9 Mar 2015
Last updated
1 Jun 2026
Results posted
No
Data monitoring committee
No

Publications

  • Talbot HK, Coleman LA, Zhu Y, Spencer S, Thompson M, Cheng PY, Sundaram ME, Belongia EA, Griffin MR. Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults. BMC Infect Dis. 2015 Apr 23;15:195. doi: 10.1186/s12879-015-0926-8.

    PubMed 25903659

Questions about this trial

What is this clinical trial studying?

An observational study of Aging, run by Vanderbilt University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maintenance of Immune Response using Hemagglutinin inhibition titers (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02401893, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in